SANTA CRUZ BIOTECHNOLOGY, INC.

Hydroxyprogesterone (HPRO-1): sc-57196

BACKGROUND

Hydroxyprogesterone (also referred to as 17α Hydroxyprogesterone) functions as a C-21 steroid hormone. An intermediary hormone in cortisol synthesis produced during glucocorticoid and sex steroid synthesis, Hydroxyprogesterone interacts with most progesterone receptors. Although the terminology is similar, Hydroxyprogesterone is not the same compound as Hydroxyprogesterone caproate; Hyroxyprogesterone is a natural progestin which elevates during the third trimester of pregnancy, mostly because of fetal adrenal formulation. Contrarily, Hydroxyprogesterone caproate is a synthetic hormone very similar in structure to both megestrol acetate and medroxyprogesterone acetate. Hydroxyprogesterone originates in the adrenal glands and also slightly in the gonads, specifically the corpus luteum of the ovary. Hydroxyprogesterone may reduce the risk of preterm delivery.

REFERENCES

1. Sexton, D.J., O'Reilly, M.W., Friel, A.M. and Morrison, J.J. 2004. Functional effects of 17α Hydroxyprogesterone caproate (17P) on human myometrial contractility *in vitro*. Reprod. Biol. Endocrinol. 2: 80.
2. Agostini, R., Casini, M.L., Costabile, L., Paragona, M., Marzano, F. and Unfer, V. 2005. Efficacy and safety of 17α Hydroxyprogesterone caproate in hormone replacement therapy. Gynecol. Endocrinol. 21: 265-267.
3. Shimizu, Y. 2005. 17 α hydroxyprogesterone. Nippon Rinsho 63: 344-346.
4. Pushpalatha, T., Reddy, P.R. and Reddy, P.S. 2005. Gestational exposure to Hydroxyprogesterone caproate suppresses reproductive potential in male rats. Naturwissenschaften 92: 385-388.
6. Petrini, J.R., Callaghan, W.M., Klebanoff, M., Green, N.S., Lackritz, E.M., Howse, J.L., Schwarz, R.H. and Damus, K. 2005. Estimated effect of 17 α Hydroxyprogesterone caproate on preterm birth in the United States. Obstet. Gynecol. 105: 267-272.
5. Meis, P.J. 2005. 17 Hydroxyprogesterone for the prevention of preterm delivery. Obstet. Gynecol. 105: 1128-1135.
7. Pau, D.A., Mackley, A. and Bartoshesky, L. 2006. Newborn screening levels of 17 Hydroxyprogesterone in very low birth weight infants and the relationship to chronic lung disease. J. Pediatr. Endocrinol. Metab. 19: 1119-1124.
8. Paonessa, D.J., Shields, A.D., Howard, B.C., Gotkin, J.L., Deering, S.H., Hoeldtke, N.J. and Napolitano, P.G. 2006. 17 Hydroxyprogesterone caproate reverses induced vasoconstriction of the fetoplacental arteries by the thromboxane mimetic U46619. Am. J. Obstet. Gynecol. 195: 1011-1014.
9. Chong, H., Cheah, S.H., Ragavan, M. and Johgalingam, V.T. 2006. Production and characterization of monoclonal antibodies against 17α Hydroxyprogesterone. Hybridoma 25: 34-40.

SOURCE

Hydroxyprogesterone (HPRO-1) is a mouse monoclonal antibody raised against 17 α Hydroxyprogesterone conjugated to BSA.

PRODUCT

Each vial contains 100 µg IgG_3 in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

Hydroxyprogesterone (HPRO-1) is recommended for detection of Hydroxyprogesterone by solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000); also recommended for detection of 17 Hydroxyprogesterone. Non cross-reactive with BSA.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.